Semaglutide's Broad Efficacy in Obesity and Type 2 Diabetes Confirmed

Obesity and type 2 diabetes are pervasive global health challenges, frequently co-occurring and significantly increasing the risk of serious complications like cardiovascular disease. While GLP-1 receptor agonists, such as liraglutide, have provided effective therapeutic options, there remains an ongoing need for highly potent and well-tolerated treatments to manage these chronic metabolic conditions. This review synthesizes extensive clinical trial evidence from the Semaglutide Treatment Effect in People with Obesity (STEP) program to comprehensively evaluate semaglutide's full spectrum of efficacy and safety across both obesity and type 2 diabetes populations.